

Data Sheet (Cat.No.T17066)



Umbralisib hydrochloride

Chemical Properties

CAS No.: 1532533-78-0 Formula: C31H25ClF3N5O3

Molecular Weight: 608.01
Appearance: N/A

Storage: 0-4°C for short term (days to weeks), or -20°C for long term (months).

Biological Description

Description	Umbralisib hydrochloride is a novel PI3K δ inhibitor (IC50 and EC50 of 22.2 nM and 24.3 nM, respectively). Umbralisib hydrochloride is also active against CK1 ϵ (EC50: 6.0 μ M).		
Targets(IC ₅₀)	PI3Kδ: 22.2 nM		
In vitro	Umbralisib causes a half-maximal inhibition of human whole blood CD19 cell proliferation between 100-300 nM. Umbralisib (10 nM-100 μ M) inhibits phosphorylated AKT at Ser473 in a concentration-dependent manner in human lymphoma and leukemia cell lines. Umbralisib and carfilzomib synergistically kill blood cancer cells by disrupting the 4E-BP1-elF4F-c-Myc axis. Umbralisib (15-50 μ M) potently represses the expression of c-Myc in the DLBCL cell line LY7 and is uniquely characterized with structural features suitable for targeting CK1 ϵ in lymphoma cells. Umbralisib and carfilzomib in combination synergistically and selectively silence the c-Myc and E2F transcription programs [1][2].		
In vivo	In a subcutaneous xenograft model of T-cell acute lymphoblastic leukemia in NOD/SCID mice using the MOLT cell line, Umbralisib (TGR-1202; 150 mg/kg, daily p.o.) obviously shrinks the tumors by day 25 [2].		

Solubility Information

Solubility	DMSO: 150 mg/mL (246.71 mM) (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.645 mL	8.224 mL	16.447 mL
5 mM	0.329 mL	1.645 mL	3.289 mL
10 mM	0.164 mL	0.822 mL	1.645 mL
50 mM	0.033 mL	0.164 mL	0.329 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

Reference

2. Deng C, et al. Silencing c-Myc translation as a therapeutic strategy through targeting PI3K δ and CK1 ϵ in hematological malignancies. Blood. 2017 Jan 5;129(1):88-99

Page 1 of 2 www.targetmol.com

Inhibitors · Natural Compounds · Compound Libraries

This product is for Research Use Only \cdot Not for Human or Veterinary or Therapeutic Use.

Tel:781-999-4286

E-mail:info@targetmol.com

Address:36 Washington Street, Wellesley Hills, MA 02481

Page 2 of 2 www.targetmol.com